INFORMATION DISCLOSURE
STATEMENT BY APPLICANT
(Not for submission under 37 CFR 1.99)

Application Number		09684883	
Filing Date		2000-10-06	
First Named Inventor	Bernard R. Brodeur		
Art Unit		1645	
Examiner Name	Albert	Mark Navarro	
Attorney Docket Numb	er	484112.417C1	

					U.S.	PATENTS		Ren	iove	
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue C)ate	of cited Document		Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear		
	1	5106726		1992-04	-21	Wang				
If you wisl	h to a	dd additional U.S. Pate	nt citatio	n inform	ation pl	ease click the	Add button.	A	id	
			U.S.P	ATENT	APPLI	CATION PUBL	LICATIONS	Ren	iove	
Examiner Initial*	Cite No	Publication Number	Name of Patentee or Applicant Relevant Passages or							
	1									
If you wisl	h to a	dd additional U.S. Publi	ished Ap	plication	citatio	n information p	lease click the Ad			
				FOREIG	3N PAT	ENT DOCUM	ENTS	Ren	nove	
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code ⁴	Publication Date	Name of Patente Applicant of cited Document	or where	s,Columns,Lines Relevant iges or Relevant es Appear	тя
	1									
If you wisl	h to a	l dd additional Foreign P	atent Do	cument	citation	information pl	ease click the Add	button A	id	_
			NON	I-PATE	NT LITE	RATURE DO	CUMENTS	Ren	nove	
Examiner Cite Initials* Comparison (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.							T5			

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		09684883	
Filing Date		2000-10-06	
First Named Inventor	Bernard R. Brodeur		
Art Unit		1645	
Examiner Name	Albert	Mark Navarro	
Attorney Docket Number		484112.417C1	

Date Considered

	1	CANNON et al., "Monodonal Antibody that Recognizes an Outer Membrane Antigen Common to the Pathogenic Neisseria Species but not to Most Nonpathogenic Neissera Species," Infection and Immunity 43(3):994-999, March 1984					
	2	COSTA et al., "Meningococcal Disease in São Paulo, Brazil," NIPH Annais 14(2):215-218, December 1991,					
	3	GOLDSCHNEIDER et al., "Human immunity to the Meningococcus. The Role of Humoral Antibodies," Journal of Experimental Medicine 129 1307-1328, 1989.					
	4	GOLDSCHNEIDER et al., "Human immunity to the Meningococcus Development of Natural Immunity," Journal of Experimental Medicine 129:1327-1348, 1969.					
	5	SIERRA et al., "Vaccine Against Group B Neisseria Meningitidis: Protection Trial and Mass Vaccination Results in Cuba.," NIPH Annais 14(2) 195-210, December 1991.					
	6	WANG et al., "Development of a Nesseria meningfildis Group B Serotype 2b Protein Vaccine and Evaluation in a Mouse Model," Infection and Immunity 46(2):408-414, November 1994.					
	7	WEDEGE et al., "Human Immunoglobulin G Subciass Immune Response to Outer Membrane Antigens in Meningococcal Group B Vaccine." Journal of Clinical Microbiology 25(8) 1349-1353, August 1987.					
	8	ZOLLINGER et al., "Menngococcal Serogroup B Vaccine Protection Trial and Follow-up Studies in Chile," NIPH Annais 14(2):211-213, December 1991.					
If you wish	f you wish to add additional non-patent literature document citation information please click the Add button Add						
EXAMINER SIGNATURE							

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1-see Knd Codes of USPTD Patent Documents at https://www.USPTD.600/ or MPEP 90104. I Enter office that issued the document, by the two-letter codes (MPD)

See Kink Codes of USPTO Patent Documents at view_USPTO_GOV or MPEP 8019A. Finter office that issued the document, by the two-letter (or MPD-Standard ST3.) First planeses peated focuments, the inclination of the year of the region or the Emperor unspreaded here said insuffered here planed document. A fund of coursent by the epipropriate symbios as indicated on the document under WIPO Standard ST.16 if possible, "Applicant is to place a check mark here if Emploits harquages treatables on adtached."

Examiner Signature

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

	Application Number		09684883		
	Filing Date		2000-10-06		
	First Named Inventor	Berna	ard R. Brodeur		
	Art Unit		1645		
Examiner Name Albert		Albert	t Mark Navarro		
	Attorney Docket Number		484112 417C1		

CERTIFICATION STATEMENT

Please see 37	CFR 1	.97 and	1.98 to make the	appropriate	selection(s)	
---------------	-------	---------	------------------	-------------	------------	----	--

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. Sea 37 CFF 1.97(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 156(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 197(e)(c).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

Mae Inanne Rosek

Name/Print

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

Registration Number

48 903

Signature	/Mae Joanne Rosok/	Date (YYYY-MM-DD)	2007-03-20

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file and by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from to the USPTO. There will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. operatment of Comments o

Privacy Act Statement

The Privacy Act of 1974 (P. L. 95-79) requires that you be given centain information in connection with your submission of the stacked form related to a penter application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is SU S. C. (2b)(2); (2) furnishing of the information solicided to is coluntary, and (3) the principal purpose for which the information is used by the U.S. Patent and Trademan XOTIEs is to process and/or examine your submission related to a patent agricultant or patent. If you do not furnish the requested process and/or examine your submission related to a patent agricultant or patent. If you do not furnish the requested requirement of the patent of the

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing coursel in the course of settlement negotiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the suited matter of the record
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S. C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals or part individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
 application pursuant to 35 U.S. C. 151. Further, a record may be
 disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the accord was filed in application
 which became abandoned or in which the proceedings were terminated and which application is referenced by either a
 published application, an application peen to public inspections or an issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.